Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities
Cytochrome P4501A2 (CYP1A2) and N-acetyltransferase-2 (NAT2) are hepatic enzymes that may activate some procarcinogens. Previous reports have determined CYP1A2 and NAT2 phenotypes by quantitating relative amounts of urinary caffeine and metabolites. However, a number of experimental issues with this...
Gespeichert in:
Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 1995-03, Vol.4 (2), p.139-146 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Cytochrome P4501A2 (CYP1A2) and N-acetyltransferase-2 (NAT2) are hepatic enzymes that may activate some procarcinogens. Previous
reports have determined CYP1A2 and NAT2 phenotypes by quantitating relative amounts of urinary caffeine and metabolites. However,
a number of experimental issues with this approach remain. To address these, we measured caffeine and 4 metabolites in urine
samples from 20 healthy volunteers on 3 separate occasions at 7-day intervals. Two additional volunteers were studied to measure
the pattern of excretion of these analytes in urine over time. The molar ratio of two compounds (1,7-dimethylxanthine/1,3,7-trimethylxanthine)
was used to phenotype CYP1A2, while the molar ratio of two other compounds (5-acetylamino-6-formylamino-3-methyluracil/1-methylxanthine)
served to phenotype NAT2. Within-subject variation was less than 25% for most participants. In instances when within-subject
variation of the metabolic ratio was > 25%, metabolite peaks were usually present in one or more control urine samples. Some
caffeine metabolites were observed in urine samples at detectable levels up to 48 h after caffeine ingestion. We conclude
that: (a) this assay for determining CYP1A2 and NAT2 activities (phenotyping) has an acceptably low within-subject variation
over 3 consecutive weeks for most subjects who were caffeine-free for 36 h prior to study; (b) collecting and analyzing urine
samples prior to testing can indicate if subjects are excreting caffeine metabolites and will aid in locating metabolite peaks
on chromatograms; (c) refraining from caffeine for 48 h before testing is the best compromise between convenience for the
subject and obtaining reproducible results; (d) determining metabolite molar ratios in urine collected 4-5 h after ingesting
caffeine provides an acceptable time for the measurement; and (e) different ratios of metabolites for determining CYP1A2 phenotype
have different advantages. |
---|---|
ISSN: | 1055-9965 1538-7755 |